• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·CORALAB.BO
Share

Coral Laboratories Limited Stocks

₹ 556.15Last Updated 27.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

₹ 21.54M

₹ 556.15
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Coral Laboratories Ltd. specializes in the production of various pharmaceutical drug formulations. The company's operations are segmented geographically across Ethiopia, India, and other international territories. Its comprehensive product line encompasses solid dosage forms like tablets and capsules, liquid medications, topical treatments, ophthalmic and otic solutions, and injectable preparations. Founded on June 19, 1981, the firm's main corporate office is located in Mumbai, India.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.07.2026 22:06

Novo Will Sue Investors Over the Results of a Study on a Weight-Loss Drug

29.07.2026 21:47

Insiders in the AI boom were among the biggest sellers on the eve of the chipmakers' crash

29.07.2026 20:35

Noble is first on Wall St. to cover Beasley Broadcast Group, seeing almost 50% upside

29.07.2026 19:56

"The Focus Is Back on Iran": U.S. Stocks See a Sell-Off Ahead of the Fed's Decision

29.07.2026 19:38

"I've been through hell": July could be the worst month in history for Korean stocks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026